US EditionPublished • loading... • Updated
Eczema Injectable Drug Provides Quick Itch Relief, Clinical Trial Results Show
Nemolizumab relieved itch within two days for three times as many eczema patients as placebo and doubled the number reporting better sleep, researchers found.
- On Friday, Dec. 19, 2025, researchers reported Nemolizumab relieved itchiness within two days for three times as many patients as placebo.
- Eczema results from immune-system dysfunction, and researchers performed a follow-up analysis of the pivotal trials that supported U.S. Food and Drug Administration approval in 2024.
- Results showed measurable changes within 48 hours, with nemolizumab reducing itch for nearly 11% of patients versus 3% on placebo and sleep improving for 10% of eczema patients and more than 13% of prurigo nodularis patients within two days.
- Study authors emphasized clinical benefits for patients, noting itch is the most burdensome symptom for moderate-to-severe atopic dermatitis and prurigo nodularis, making rapid relief a key treatment goal.
- The analysis of nearly 2,300 people suggests findings published by Sonja Ständer et al. in the Journal of the European Academy of Dermatology and Venereology and publicized in a Galderma news release Dec. 17, 2025.
Insights by Ground AI
21 Articles
21 Articles
Coverage Details
Total News Sources21
Leaning Left5Leaning Right4Center3Last UpdatedBias Distribution42% Left
Bias Distribution
- 42% of the sources lean Left
42% Left
L 42%
C 25%
R 33%
Factuality
To view factuality data please Upgrade to Premium
